293 related articles for article (PubMed ID: 31216823)
1. [Role of PD-1/PD-L1 in microenvironment of breast cancer].
Ji P; Gong Y; Hu X
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):401-405. PubMed ID: 31216823
[TBL] [Abstract][Full Text] [Related]
2. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
3. [Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors].
Huang HF; Zhu H; Yang XT; Guo XY; Li SS; Xie Q; Tian XB; Yang Z
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):410-414. PubMed ID: 31216825
[TBL] [Abstract][Full Text] [Related]
4. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
[TBL] [Abstract][Full Text] [Related]
5. The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Chen JX; Yi XJ; Gao SX; Sun JX
Gen Physiol Biophys; 2020 Jul; 39(4):319-330. PubMed ID: 32902402
[TBL] [Abstract][Full Text] [Related]
6. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
[TBL] [Abstract][Full Text] [Related]
7. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
8. PD-1 /PD-L1 checkpoint in hematological malignancies.
Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract][Full Text] [Related]
10. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.
Qin W; Hu L; Zhang X; Jiang S; Li J; Zhang Z; Wang X
Front Immunol; 2019; 10():2298. PubMed ID: 31636634
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and its ligands are important immune checkpoints in cancer.
Dong Y; Sun Q; Zhang X
Oncotarget; 2017 Jan; 8(2):2171-2186. PubMed ID: 27974689
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
13. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
14. Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs.
Ding L; Lu S; Li Y
Pathol Oncol Res; 2020 Apr; 26(2):651-663. PubMed ID: 31748880
[TBL] [Abstract][Full Text] [Related]
15. [The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].
Piętak P; Pietrzyk N; Pawłowska A; Suszczyk D; Bednarek W; Kotarski J; Wertel I
Wiad Lek; 2018; 71(5):1089-1094. PubMed ID: 30176647
[TBL] [Abstract][Full Text] [Related]
16. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
17. Correlation of PD-1/PD-L1 Signaling Pathway with Treg/Th17 Imbalance from Asthmatic Children.
Xi X; Liu JM; Guo JY
Int Arch Allergy Immunol; 2018; 176(3-4):255-267. PubMed ID: 29874664
[TBL] [Abstract][Full Text] [Related]
18. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
Monneur A; Gonçalves A; Bertucci F
Bull Cancer; 2018 Mar; 105(3):263-274. PubMed ID: 29455872
[TBL] [Abstract][Full Text] [Related]
19. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
